Matrix Metalloproteinase-9 in an Exploratory Trial of Intravenous Minocycline for Acute Ischemic Stroke

Plasma matrix metalloproteinase-9 levels predict posttissue plasminogen activator (tPA) hemorrhage. The authors investigated the effect of minocycline on plasma matrix metalloproteinase-9 in acute ischemic stroke in the Minocycline to Improve Neurological Outcome in Stroke (MINOS) trial and a compar...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Stroke (1970) 2011-09, Vol.42 (9), p.2633-2635
Hauptverfasser:	SWITZER, Jeffrey A, HESS, David C, ERGUL, Adviye, WALLER, Jennifer L, MACHADO, Livia S, PORTIK-DOBOS, Vera, CREED PETTIGREW, L, CLARK, Wayne M, FAGAN, Susan C
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Anti-Bacterial Agents - administration & dosage Biological and medical sciences Blood. Blood coagulation. Reticuloendothelial system Brain Ischemia - blood Brain Ischemia - drug therapy Female Fibrinolytic Agents - administration & dosage Humans Infusions, Intravenous Male Matrix Metalloproteinase 9 - blood Matrix Metalloproteinase Inhibitors Medical sciences Middle Aged Minocycline - administration & dosage Neurology Pharmacology. Drug treatments Stroke - blood Stroke - drug therapy Thrombolytic Therapy - methods Tissue Plasminogen Activator - administration & dosage Vascular diseases and vascular malformations of the nervous system
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Plasma matrix metalloproteinase-9 levels predict posttissue plasminogen activator (tPA) hemorrhage. The authors investigated the effect of minocycline on plasma matrix metalloproteinase-9 in acute ischemic stroke in the Minocycline to Improve Neurological Outcome in Stroke (MINOS) trial and a comparison group. Matrix metalloproteinase-9 level decreased at 72 hours compared with baseline in MINOS (tPA, P=0.0022; non-tPA, P=0.0066) and was lower than in the non-MINOS comparison group at 24 hours (tPA, P
ISSN:	0039-2499 1524-4628
DOI:	10.1161/STROKEAHA.111.618215